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3  Abstract 
In recent years, a great effort has been deployed towards a better understanding of the molecular 
changes in cells and in the bone marrow (BM) environment that contribute to the development 
and progression of myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML). 
Among others, the aberrant hematopoietic stem cells in MDS often display increase in DNA 
double strand breaks, genomic instability with common loss or rearrangement of chromosomes 
and an ineffective response to DNA damage, a phenomenon that has been linked to the onset 
of cellular senescence. Additionally, the BM microenvironment can become more pro-
inflammatory. 
In our effort to better understand the contribution of the BM microenvironment on MDS 
progression, we analyzed the expression profiles of cytokines in the BM microenvironment in 
all stages of MDS/AML and found several proinflammatory cytokines that increase with 
disease progression. Also, by repeated sampling of patients over the course of 5-azacytidine 
therapy, we were able to assess the changes in the proinflammatory cytokine milieu with the 
progression of the disease.  
Additionally, we aimed to identify the candidate markers for the improvement of MDS 
prognosis. We focused on naturally occurring germline polymorphism of NAD(P)H 
dehydrogenase (quinone 1) gene (NQO1*2) that diminishes the ability to reduce oxidative 
stress. We uncovered that patients with NQO1*2 genotype progress faster and have a shorter 
overall expression, especially pronounced in low-risk MDS with normal karyotype. Moreover, 
the NQO1*2 genotype was associated with higher sensitivity to increased ferritin levels. We 
suggest that NQO1*2 polymorphism can be used as a prognostic marker.  
Further, in a subset of low-risk MDS patients treated with lenalidomide, we found that the 
combination of lenalidomide and prednisone and/or erythropoietin had a positive impact on 
relapsed and refractory patients with del(5q) MDS.  
Next, we focused on the characterization of virtual memory (VM) CD8+ T-cells. The 
diminishment of this population was recently identified in chronic myeloid leukemia. Thus it 
is possible that VM T-cells could play a role in MDS pathology as well. We discovered that 
VM T-cell development is determined by their T-cell receptor self-reactivity. Moreover, by 
analyzing the expression profiles of antigen-experienced memory T-cells and VM T-cells, we 
uncovered that VM T-cells acquire a partial memory program. However, this does not make 
them more potent in inducing autoimmunity when compared to naïve cells with the same T-cell 
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receptor. Thus, we postulate that VM T-cell formation from highly self-reactive T-cell receptor 
clones could function as a novel self‐tolerance mechanism.  
Finally, we compared findings of the different subsets of antigen-inexperienced memory 
T-cells and concluded that VM T-cells and lymphopenia-induced memory T-cells likely 
represent one subset of antigen-inexperienced memory T-cells. We have proposed to call this 
subset “homeostatic memory T-cells”. 
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4 Abstract (Czech version) 
V posledních letech byla vynaložena velká snaha o lepší pochopení molekulárních změn v 
buňkách a v prostředí kostní dřeně, které přispívají k rozvoji a progresi myelodysplastického 
syndromu (MDS) do akutní myeloidní leukémie (AML). Aberantní hematopoetické kmenové 
buňky v MDS často vykazují nárůst dvojitých zlomů DNA, genomovou nestabilitu s běžnou 
ztrátou nebo přestavbou chromozomů a neúčinnou odpověď na poškození DNA. Navíc může 
být mikroprostředí kostní dřeně více prozánětlivé.  
Pokusili jsme se lépe porozumět příspěvku mikroprostředí kostní dřeně při progresi MDS. 
Analyzovali jsme expresní profily cytokinů v mikroprostředí kostní dřeně u všech stadií 
MDS/AML a našli jsme několik prozánětlivých cytokinů, jejichž hladiny se zvyšují s progresí 
onemocnění. Opakovaně jsme odebírali vzorky kostní dřeně od MDS pacientů v průběhu léčby 
5-azacytidinem a podařilo se nám stanovit změny v cytokinovém prostředí v průběhu progrese 
onemocnění. 
Dále jsme se zaměřili na identifikaci kandidátních markerů pro zlepšení prognózy MDS. 
Zaměřili jsme se na přirozeně se vyskytující polymorfismus genu NAD (P) H dehydrogenázy 
(chinonu 1) (NQO1*2), který snižuje schopnost redukovat oxidační stres. Zjistili jsme, že 
pacienti s genotypem NQO1*2 se zhoršují rychleji a mají kratší celkovou dobu přežití, což 
bylo zvláště patrné u MDS pacientů s nízkým rizikem progrese do AML a normálním 
karyotypem. Navíc byl genotyp NQO1*2 spojený s vyšší citlivostí na zvýšené hladiny feritinu. 
Navrhujeme tedy použití polymorfismu v NQO1*2 jako prognostického markeru. 
Navíc jsme zjistili u skupiny MDS pacientů léčených lenalidomidem, že kombinace 
lenalidomidu a prednisonu a/nebo erytropoetinu má pozitivní dopad na relapsované a 
refrakterní pacienty s MDS del(5q). 
Dále jsme se zaměřili na charakterizaci virtuálních paměťových (VM) CD8+ T-buněk. Snížení 
této populace bylo nedávno zjištěno u chronické myeloidní leukémie. Je tedy možné, že VM 
T-buňky mohou hrát také roli v patologii MDS. Zjistili jsme, že vývoj VM T-buněk je 
determinován autoreaktivitou jejich T-buněčného receptoru. Porovnáním expresních profilů 
pravých paměťových T-buněk a VM T-buněk jsme zjistili, že VM T-buňky získávají částečný 
paměťový program. To však neznamená, že jsou účinnější při indukci autoimunity v porovnání 
s naivními buňkami se stejným T-buněčným receptorem. Předpokládáme tedy, že tvorba VM 
T-buněk z vysoce autoreaktivních T-buněk by mohla fungovat jako nový mechanismus 
autotolerance. 
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Nakonec jsme porovnali poznatky o různých podskupinách paměťových T-buněk, které 
vznikly bez předchozího kontaktu s antigenem a dospěli jsme k závěru, že VM T-buňky a 
paměťové T-buňky vzniklé díky lymfopenii pravděpodobně představují jednu podskupinu 
antigen-nezkušených paměťových T-buněk. Navrhujeme pro ně souhrnný název 
"homeostatické paměťové T-buňky". 
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6 Introduction 
Hematopoiesis is a hierarchical process that begins in the bone marrow (BM) when 
hematopoietic stem cells (HSC) enter the cell cycle and give rise to the lineage precursors that 
further differentiate into more specific cell types of myeloid, erythroid or lymphoid lineage. In 
normal hematopoiesis, this process is tightly regulated to replenish the blood cells within the 
organism while sustaining a sufficiently large HSC pool for proper blood production.  
Although the majority of blood cells absolve their entire differentiation process in the BM 
tissue, for T-cell precursors it is necessary to leave BM and travel to the thymus, where they 
can fully mature. It is within the confinement of the thymus, where thymocytes go through the 
process of recombining the genes encoding for T-cell receptor chains. T-cell receptor 
recombination is accompanied by a selection process ensuring that only cells with relatively 
low but sufficient self-reactivity are released into the periphery.  
 
6.1 Role of mature T-cells in hematopoiesis  
The mature T-cells populate different niches within the whole body including the BM. 
However, the abundance of cell types in the lymphoid organs and in the BM differ significantly. 
It has been noted that there is a substantial population of T-cells within the BM and that the 
BM T-cell compartment has a higher proportion of cells with memory phenotype than in 
peripheral blood or lymph nodes. However, there is some controversy regarding the 
recirculation and homeostatic proliferation of these cells. So far, the main approaches deployed 
in assessing the proliferation status of these cells were in vivo labelling with 
bromodeoxyuridine (BrdU) [1, 2], adoptive transfer of carboxyfluorescein diacetate 
succinimidyl ester (CFSE) labelled cells [3], staining with proliferation marker Ki-67 [4, 5] 
and in vivo stable radioisotope labelling [6].  
Because of the known side-effects of long-term BrdU labelling [7] and the need to label cells 
with CFSE ex vivo, the studies performed using the latter methodologies give more precise 
results without perturbing the BM niche. Studies using Ki-67 staining concluded that more than 
90% of murine memory CD8+ T-cells are in the G0 phase of the cell cycle, in accordance with 
the analysis of human BM T-cells. Moreover, the majority of T-cells in BM are of the memory 
phenotype and lack the ability to leave the BM tissue due to the expression of CD69 [8]. 
Recently, in vivo murine studies of normal hematopoiesis have shown that the presence of 
CD8+ T-cells with the memory phenotype enhances the proliferation and self-renewal of the 
healthy HSC. Also, the mice lacking CD8+ T-cells with the memory phenotype have 
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significantly fewer HSC, a situation that can be remedied by the adoptive transfer of CD8+ 
memory T-cells [9]. Moreover, the dynamic alterations in the T-cell compartment have been 
shown to contribute to the pathological manifestations of myeloid leukemias. 
  
6.2 Functional integrity of HSC  
During aging, the functional integrity of HSC can be influenced by acquiring somatic mutations 
that could give them a selective advantage in entering the cell cycle and can result in the 
pathophysiological differentiation and development of hematologic malignancies.  
Additionally, HSC cell fate is regulated in response to chronic inflammatory stimuli. The long-
term inflammation in the BM has been shown to skew the differentiation of HSC, to impair the 
fitness of normal HSC and to contribute to the development of diseased states, such as in the 
myelodysplastic syndromes (MDS) or in acute myeloid leukemia (AML). Inflammation is one 
of the most adverse co-founding in MDS diagnosis that is found in 10% patients [10-12]. The 
impact of the chronic inflammation is demonstrated in the increase of the incidence and earlier 
onset of the MDS [13, 14].  
Both MDS and AML are characterized by aberrant expansion of immature hematopoietic 
precursors called blasts, defined by expression of CD34 molecule. The MDS is a very 
heterogeneous HSC disease with various disease manifestations that is classified into several 
subtypes [15] and stratified with regard to the risk of progression into AML. In low-risk MDS, 
the expansion of blasts is localized to the BM and the process of maturation is inefficient due 
to increased apoptosis of blasts. This leads to insufficient peripheral blood cell counts, i.e. 
cytopenia (anemia, thrombocytopenia, neutropenia). In high-risk MDS, the aberrant HSC 
becomes resistant to the induction of apoptosis and increasingly proliferate. Ultimately, in the 
final stage of the disease (AML), the blasts are released to the bloodstream, which is correlated 
with the short overall survival (OS) of the affected individuals.  
 
6.3 The immune system dysregulation in MDS 
Interestingly, 28% of MDS cases present autoimmune manifestations [16] and the history of 
autoimmune diseases increases the risk of developing MDS or AML [13, 14].  
Multiple immune cell subsets have been recognized to contribute to the development and 
manifestations of the MDS. The proinflammatory microenvironment contributes to the 
expansion of the aberrant MDS blasts [17], causes abnormalities in natural killer (NK) cells 
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[18] and T-regulatory lymphocytes (Treg) and supports the development of specialized 
myeloid derived suppressor cells (MDSC) [19, 20]. 
 
6.3.1 Myeloid-derived suppressor cells (MDSC) 
MDSCs are a group of immature myeloid cells that develop over the course of major 
inflammatory processes and infections in order to alter the response of the innate immune 
system to stress. MDSCs have the ability to suppress T-lymphocyte function. Interestingly, 
MDSCs have been found in increased numbers in MDS and it has been suggested that these 
cells can play a role in the development [21] and progression [22] of MDS, where the increase 
in MDSC correlates with the expansion of Tregs and the progression of MDS [22]. 
The Gr1+ CD11b+ myeloid precursors give rise to the MDSCs via reprogramming induced by 
S100 calcium-binding protein A9 (S100A9) [23]. The S100A8/S100A9 heterodimer 
(calprotectin) belongs to a group of danger associated molecular patterns (DAMP) that are 
abundantly expressed in the myeloid cells. The formation and excretion of calprotectin are 
increased during the inflammation, where it stimulates the leukocyte recruitment to the site of 
inflammation [24, 25]. The importance of the calprotectin in the development of MDS has been 
shown using S100A9 transgenic mice overexpressing the S100A9 protein in the cells of HSC 
origin. These S100A9 transgenic mice accumulate MDSCs in BM and gradually develop 
progressive multilineage cytopenias and dysplasia resembling the phenotype of MDS [21].  
 
6.3.2 Natural killer cells  
Recently, the role of NK cells in the pathology of MDS has been thoroughly examined. Several 
reports have noted a reduction in the absolute counts of peripheral NK cells among MDS 
patients compared to age-matched healthy controls [18, 26, 27], as well as their lower 
cytotoxicity [28] that was especially pronounced in high-risk MDS. Moreover, the decreased 
cytotoxicity of NK cells has been confirmed in the BM [29].  
The loss of cytotoxicity was mainly due to the reduced expression of activating natural 
cytotoxicity receptors NKp30 and NKG2D (Killer Cell Lectin Like Receptor K1) [28], possibly 
due to the chronic exposure to their ligands on leukemic blasts [30]. This hypothesis was 
corroborated by the inability of NK cells to directly kill autologous MDS blasts [29]. The 
worsening of NK cell function might be correlated with the progression of the disease, as the 
20-50% of circulating NK cells have been shown to share karyotype abnormalities with the 
MDS blasts [27].  
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6.3.3  T-cells  
Several subsets of T-cells have been shown to play a role in the development and progression 
of MDS. Among them are CD8+ T-cells and several subsets of CD4+ T-cells, such as regulatory 
T cells (Tregs) and T helper 17 (Th17) T-cells.  
Tregs (CD4+ CD25+ FoxP3+) dampen adaptive immune response by suppressing autoreactive 
T-cells (FoxP3, Forkhead Box P3). Consequently, the contraction of Treg compartment is 
associated with autoimmunity [31], while the expansion of Tregs is intrinsic in the loss of 
immunosurveillance and promotion of tumorigenesis [32]. Both of these manifestations are 
present in MDS. In low-risk MDS low numbers of Tregs have been reported, whereas in high-
risk MDS and AML are Tregs expanded [33, 34].  
Interestingly, the quantitative imbalance of Tregs in low-risk MDS correlates with the 
increased proportion of proinflammatory Th17 T-cells and higher levels of apoptosis in the BM 
[35]. This imbalance between Tregs and Th17 numbers has been observed in many diseases of 
the BM with inflammation as one of the symptoms [36]. However, the percentage of the Th17 
cells later decreases to normal levels as the disease progresses [35].  
A portion of low-risk MDS patients presents a skewed ratio of CD4+ and CD8+ T-lymphocytes 
in the BM [33], and in some cases also in the peripheral blood [26, 37], which has been ascribed 
to the increased proliferation of CD8+ T-cells [37, 38]. A recent study using peripheral blood 
from a younger cohort of MDS patients has shown that it is the depletion of CD4+ T-cells rather 
than the enlargement of CD8+ compartment that contributes to this abnormality [39]. This 
finding however still awaits its confirmation in the BM niche as well as the inclusion of more 
aged patients. The analysis of T-cell repertoire in MDS patients has indicated the oligoclonal 
character of T-cells across all subtypes and stages of MDS [40-43]. In aplastic anemia, a BM 
failure disorder that can progress into MDS, the enlarged oligoclonally expanded CD8+ T-cell 
compartment consists of cells with the effector phenotype [44]. Similar findings were observed 
in childhood refractory cytopenia [45].  
MDS patients with abnormal proliferation of the CD8+ T-cells in BM can benefit from using 
the immunosuppressant therapy by cyclosporine A or anti-thymocyte globulin that can for 
some time subdue the progression of the disease [37, 38].  
Additionally, several in vitro studies have demonstrated the role of CD8+ T-cells in the 
suppression of malignant hematopoietic precursors [46]. Indeed, in MDS patients with trisomy 
8, the CD8+ T-cells have been shown to suppress the aberrant HSC clones via antigen-specific 
response to Wilms' tumor 1 antigen (WT1), since WT1 is located on chromosome 8 and is 
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overexpressed in cells with trisomy 8 [47]. Recently, CD4+ T-cells from AML have been shown 
to suppress the proliferation of the mesenchymal stem cells (MSC) in vitro via secreting 
miRNA 10a [48]. 
Moreover, a subset of T-cells in some cases shares chromosomal abnormalities [49] or somatic 
mutations [50] with the malignant clone. It is however unclear, whether the T-lymphocytes 
with the suppressive activity on HSC or MSC also share the chromosomal abnormalities with 
the aberrant HSC clones.  
 
6.4 Alterations of the BM niche 
Changing spectrum of the cell types within the BM niche can have an impact on the cytokines 
secreted into the BM microenvironment and thus can influence the development and 
progression of the disease.  
 
6.4.1 Stromal cells 
MSC form an important part of the BM niche and an increasing number of studies shows that 
they might contribute to the development of MDS.  
MSC derived from in vitro cultures originating in BM aspirated from MDS patients (MDS-
MSC) are characterized by slower proliferation and induce the program of senescence earlier 
than MSC derived from healthy subjects [51-54]. Recently, the group of Blau et al. analyzed 
the chromosomal aberrations in MSC and found out that the MDS-MSC bear identical 
chromosomal aberrations as the aberrant MDS clones. Additionally, they uncovered that the 
same patient can have a set of distinctly different chromosomal aberrations in HSC and in 
MDS-MSC [55].  
Moreover, isolated MSC from newly diagnosed MDS patients were able to support the in vitro 
growth and differentiation of HSC into osteoblasts, adipocytes, and chondrocytes, but their 
ability to react to proinflammatory cytokines has been modified. The in vitro grown 
unstimulated MDS-MSC were producing twice as much IL-1β (interleukin 1β) as healthy MSC 
and after addition of proinflammatory cytokines IL-1β and TNFα (tumor necrosis factor α), the 
MDS-MSC increased the production of GM-CSF (granulocyte-macrophage colony-
stimulating factor) three times more than the healthy MSC [56].  
One of the reasons that the MDS-MSC behave differently than the healthy MSC could be the 
reduction in their ability to express Dicer1. Dicer1 is endoribonuclease that cleaves RNA and 
catalyzes the production of short inhibiting miRNA (microRNA). The consequence of the 
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deletion of Dicer1 is the loss of miRNAs that exert various regulatory functions in the cell. The 
experimental loss of miRNAs induced by the inhibition of Dicer1 in MSC leads to the induction 
of senescence [57].  
The modified MSC with lower expression of Dicer1 as well as MDS-MSC are producing lower 
levels of G-CSF (granulocyte colony-stimulating factor) and much higher levels of IL-6 and 
TGFβ (transforming growth factor β) when compared to healthy MSC. These changes in the 
expression of the cytokines contribute to the reduced ability of MDS-MSC to support the 
growth of HSC in in vitro co-culture [57]. Further, the deletion of Dicer1 in mouse 
osteoprogenitors induces secondary MDS-like neoplasia [58].  
 
6.4.2 The changes in the cytokine profiles  
In the last 20 years, there have been a number of studies focusing on changes in the expression 
and secretion profiles of the cells in BM niche, either by studying the changes in cytokine 
profiles in peripheral blood plasma [59-61] or in the plasma of the BM [62, 63].  
The most prominent members among those aberrantly expressed cytokines are TNFα, IFNγ 
(interferon γ) TGFβ, IL-4, IL-6 and IL-10. From this list, IL-6 and IL-1 belong to a group of 
proinflammatory cytokines that are involved in acute inflammatory response, whereas IL-4, 
IL-10 and TGFβ are cytokines with anti-inflammatory properties.  
IFNγ plays an important role during the regulation of innate immune response and it impacts 
the regulation of adaptive immunity as well. IFNγ is produced mainly by CD4+ Th1 
lymphocytes and by NK cells and its elevated expression is characteristic for autoimmune 
diseases. Furthermore, the increased levels of IFNγ are often identified in peripheral blood and 
BM plasma of low-risk MDS patients [64]. One of the possible reasons for the increased levels 
of aberrantly expressed cytokines is the influence of polymorphisms in their receptors and 
promoters of the genes coding for cytokines, such as IL-6, TGFβ and TNFα [65, 66]. 
 
6.5 The choice of therapy in MDS 
The best supportive care for MDS patients consists of transfusions of platelets and/or 
erythrocytes and prophylactic treatment with antibiotics. Another line of treatment is based on 
the score of their Revised International Prognostic Scoring System (IPSS-R) and the patient’s 
co-morbidities and may involve HSC transplantation, the use of immunosuppressant, 
erythropoietin, or treatment with drugs such as lenalidomide, 5-azacytidine (5-AC) or 
decitabine/5-aza-2′-deoxycytidine [67, 68].  
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Lenalidomide is primarily used for the treatment of multiple myeloma, chronic lymphocytic 
leukemia and in MDS patients with del(5q). Lenalidomide binds to a cereblon (CRBN) protein 
that works as an adaptor protein for E3 ubiquitin ligase Cullin 4A (CRL4) and modifies its 
substrate specificity, thus modulating the proteasomal degradation of its target proteins. CRBN 
retargeting induces the degradation of transcription factors Ikaros and Aiolos in T-cells, leading 
to enhanced secretion of IL-2 and augmentation of immune function.  
Moreover, CRBN retargeting specifically repairs the formation of immunological synapse in 
defective T-cells in chronic lymphocytic leukemia and lymphoma via restoring the normal Rho 
GTPase activation [69]. Interestingly, one of the haploinsufficient genes in del(5q) MDS is 
DIAPH1 (Diaphanous (mDia)-related formin mDia1), a Rho GTPase effector protein. Murine 
knockout of mDia1 results in the age-dependent myelodysplastic phenotypes [70] that can be 
rescued by treatment with lenalidomide [71].  
Both 5-AC and decitabine are derivatives of cytidine that have the ability to incorporate into 
DNA in place of cytosine. The alteration of the chemical structure of 5-AC and decitabine 
compared to cytidine then modifies the CpG site structure so that the DNA methyltransferases 
are able to recognize them, but they are entrapped on the DNA during the process of the 
methylation and subsequently degraded, leading to the inhibition of DNA methylation [72-74]. 
The idea for using the hypomethylating agents was brought about in response to the discovery 
that the malignant tumor cells change the methylation profile of the cell via the 
hypermethylation of the tumor suppressor genes and/or miRNAs [75, 76]. In Europe, the use 
of 5-AC has been approved for the treatment of high-risk MDS with blasts within a range of 
10 – 30% and has been the first therapy that significantly prolongs the OS of high-risk MDS 
patients [77]. Both 5-AC and decitabine are inherently unstable compounds that are degraded 
via cytidine deaminase within a couple of hours after the injection. Besides, only about 10-20% 
of 5-AC can be incorporated into DNA via the conversion by ribonucleotide reductase while 
the remaining 80-90% is incorporated into RNA [74]. Additionally, the 5-AC incorporated into 
RNA results in the reduction of the RNA stability. One of the proteins specifically affected by 
this incorporation is the subunit 2 of ribonucleotide reductase [78]. The resulting reduction of 
the deoxyribonucleotide pools affects the rate of DNA replication and repair. Thus, 5-AC and 
decitabine have mostly non-overlapping effects on the gene expression profiles [79]. 
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6.6 Impact of MDS therapy on the immune cells 
Numerous studies have shown that the therapy with lenalidomide, 5-AC and decitabine has an 
impact on the immune cells. However, in vivo effects in patients often differ from the effects 
of these drugs on healthy in vitro stimulated cells or in vitro studies on the cell lines.  
5-AC treatment increases the expression of cancer testis antigens (CTAs) on aberrant CD34+ 
myeloid blasts. Aberrant CTA expression is a known marker for cancer recognition by the 
immune system [80], which correlates with the increase of the proportion of CD8+ T-cells able 
to recognize CTAs when compared to the state prior to starting of the treatment. Further, the 
longitudinal analysis of high-risk MDS and AML patients has not found any differences in the 
CD4+, CD8+, Tregs or MDSC cell counts in the peripheral blood over the course of therapy 
with 5-AC, when compared to the numbers before the treatment [81]. These outcomes are in 
striking difference to the results obtained by in vitro stimulation of peripheral blood cells from 
healthy donors that yielded the inhibition of the CD8+ T-cell growth, reduction in their ability 
to kill the leukemic cell line in vitro, reduction of CD4+ Th1-cell numbers and induction of the 
suppressive capacity of Tregs [82].  
Similarly, ex vivo analysis of NK cells from the peripheral blood of MDS patients treated with 
5-AC has not generated any functional impairment of NK cells [81]. Further analysis elucidated 
that the reduction in the NK cell cytotoxicity is concentration-dependent and apparent only 
when using the doses that are much higher than the approved clinical regimen dosage [81-83]. 
Additionally, several in vitro studies suggested that the lenalidomide exposure induces 
activation of phosphoinositide-3 kinase (PI3K), AP-1 (activator protein 1) and nuclear 
translocation of transcription factor NFAT2 (nuclear factor activated T-cells 2) resulting in the 
augmentation of IL-2 secretion by T-cells and phenotypic changes in NK cells, increasing their 
proliferation and cytotoxicity potential [84, 85]. However, the longitudinal analysis of NK cells 
in the blood of multiple myeloma patients has not shown any effect of the lenalidomide on the 
NK cell function [86]. Nevertheless, in vivo studies using murine models of lymphoma show 
that lenalidomide treatment results in the decreased numbers of MDSC and Tregs [87].  
 
6.7  T-cell development  
Cancer is one of the many perturbations of the organism that affect the immune system 
homeostasis. For better understanding of the role of T-cells in the adaptive immunity and 
surveillance of HSC neoplasias, it is necessary to discuss the process of their development. 
Firstly, HSC give rise to the lymphoid progenitors that migrate from the BM to the thymus, 
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where they undergo a series of developmental changes characterized by acquiring the T-cell 
specific surface markers. Upon arrival to the thymus, T-cell precursors pass through the cortex 
to the medulla of the thymus, where they are being exposed to the different microenvironments 
that help to guide their maturation.  
 
6.7.1  T-cell development in the thymus 
The T-cell precursors inside the thymus are called thymocytes. Shortly upon the arrival to the 
thymus, thymocytes have not yet started to express the lineage defining co-receptors CD4 or 
CD8, and are thus called double negative (DN) cells. The DN developmental stage can be 
further subdivided by their expression of the α-chain of IL-2 receptor CD25 and by the 
glycoprotein CD44.  
Firstly, DN thymocytes start expressing CD44, followed by the co-expression of CD44 and 
CD25 at DN2 stage, while the third stage of the DN is defined as CD25+ CD44-. DN3 
thymocytes initiate the process of recombination of their T-cell receptor (TCR) that will define 
their specificity to recognize foreign antigens [88]. TCR is a membrane protein comprised of 
two subunits, typically α and β that are covalently linked via a disulfide bond. The well-defined 
sequential order of VDJ recombination begins with the rearrangement of the β-chain of TCR 
in DN3 thymocytes, specifically by the joining of D (diversity) and J (joining) segments, 
followed by the V-DJ segment rearrangement (V, variable).  
The VDJ rearrangement is initiated by the recombination activating genes RAG1 and RAG2 
that cooperatively bind the recombination signal sequences surrounding the segments to-be-
rearranged. The RAG proteins then initiate DNA double strand breaks at the recognition 
sequences between the segments of VDJ genes [89]. The rearranged segment ends are then 
processed and rejoined through the non-homologous end joining (NHEJ) DNA repair pathway 
[90]. The lack of precision of NHEJ can result in the addition or deletion of several nucleotides 
which subsequently shifts the open reading frame, and the rearranged TCRβ is not able to yield 
in-frame protein product [91].  
In the event of the first attempt to rearrange TCRβ chain being unsuccessful, the rearrangement 
is initiated at the second segment. The DN thymocytes that fail to rearrange TCRβ chain for 
the second time are eliminated by the apoptosis [92].  
After the successful rearrangement, TCRβ chain is expressed and transported onto the cell 
membrane, where it pairs with the surrogate chain pre-Tα and forms a pre-TCR complex with 
the newly expressed CD3 molecules. The signaling through pre-TCR triggers maturation of 
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DN thymocyte that inhibits any further rearrangement of TCRβ chain, a process called allelic 
exclusion [93]. Thymocytes then initiate the expression of both CD4 and CD8 co-receptor 
molecules and are called double positive (DP) thymocytes [94].  
Another defining characteristic of DP cells is the loss of CD25 expression and re-expression 
of the RAG genes that are required for the TCRα chain rearrangement. Interestingly, TCRα 
chain rearrangement can occur simultaneously at both chromosomes. It is however very 
unlikely that both TCRα chains will rearrange productively. Additionally, two resulting TCRα 
chains will have different functional receptor specificities and binding affinities [95]. 
 
6.7.2 Positive and negative selection 
After successful TCRα rearrangement, DP thymocytes migrate to the cortico-medullary 
junction in the thymus, where they go through the process of positive and negative selection. 
The positive selection is mediated via the cortical epithelial cells that express Class I or Class 
II of major histocompatibility complex (MHC) proteins on their surface. Additionally, the 
MHC proteins are embedded with the spectrum of self-peptides. In order to survive and to 
proceed through the maturation, the DP thymocytes have to be able to bind to these self-MHC 
proteins with a sufficient affinity to receive the survival signal. The ability of DP thymocytes 
to bind to the Class I MHC will result in the maturation to CD8+ T-cell, while the positive 
selection on Class II MHC will produce a CD4+ T-cell. The remaining functionally 
incompetent DP thymocytes that are unable to receive the survival signal will be eliminated 
via a process called “death by neglect” [96]. 
Next, the positively selected surviving cells will migrate further towards the cortico-medullary 
junction and undergo the process of negative selection with the purpose of eliminating the 
highly self-reactive cells. In this new microenvironment, the self-antigens are presented on a 
different subset of antigen presenting cells (APC) called medullary thymic epithelial cells 
(mTEC) that have the ability to express a vast range of tissue specific antigens due to the 
activation of autoimmune regulator gene [97]. Additionally, the tissue specific antigens are 
transferred to the nearby thymic dendritic cells (DC) that are present in higher numbers [98]. 
The strong-enough reaction of DP thymocytes with the mTEC will culminate in the induction 
of apoptosis. This process should theoretically result in the elimination of all highly auto-
reactive T-cells and is backed-up by the mechanism of production of Tregs from the highly 
self-reactive T-cells [99].  
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At the late stage of the positive selection, DP thymocytes terminate the expression of CD8 co-
receptor molecule and give rise to CD4int CD8- thymocytes [100, 101]. The subsequent 
upregulation of the CD4 co-receptor on thymocytes that were previously able to recognize 
Class II MHC molecules will result in the continuation of TCR signaling. These cells will 
mature into the single positive CD4-expressing thymocytes (SP4) and later into CD4+ T-cells. 
The CD4int CD8- thymocytes with the ability to recognize Class I MHC molecules will have 
disrupted TCR signaling and will have to undergo co-receptor expression switch, where the 
CD4int CD8- thymocytes downregulate CD4 and upregulate CD8 expression. These single 
positive CD8 thymocytes will ultimately give rise to CD8+ T-cells upon their egress onto 
periphery.  
 
6.8  T-cell memory  
After the successful T-cell maturation process in the thymus, newly formed T-cell is released 
to the periphery as a naïve antigen inexperienced T-cell. On the periphery, a majority of mature 
αβ T-cells recirculate between blood and the lymph nodes where they sample the antigens of 
various origins embedded on the MHC molecules of the APC. When the organism encounters 
a pathogen infection, the exogenous antigens are processed by the DC with the ability to present 
these pathogen-derived antigens to T-cells. Mature DC then enter the draining lymph node and 
present the processed exogenous antigens to T-cells [102].  
Over the course of a given infection, only a few T-cell clones have the ability to recognize 
particular antigen derived from the pathogen via their TCRs. This recognition bias is caused 
by the enormous variability of the TCR repertoire. The responsive T-cell is activated via the 
binding of the cognate antigen presented on the MHC to the TCR. The resulting TCR signaling 
pathway induces a rapid proliferation and differentiation into short-lived effector T-cells and 
memory T-cells. The function of these T-cells with a memory phenotype is to facilitate long-
term protection against the possible reinfection with the same pathogen.  
The populations of different subtypes of memory T-cells can be distinguished based on the 
differential expression of the specific surface markers. Two of the most important murine 
surface markers are the adhesive glycoprotein CD44 that is found on the antigen-experienced 
T-cells and the L-selectin (CD62L) that is lost upon the T-cell activation and allows for the 
discrimination between the short-lived effectors and long-lived memory T-cells [103, 104].  
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6.8.1 Murine antigen-inexperienced memory T-cells (AIMT) 
It has been noted previously that some of the CD8+ T-cells that have never encountered their 
cognate antigen can exhibit an apparent memory phenotype – and are thus antigen-
inexperienced memory T-cells (AIMT) [105]. Three subtypes of the AIMT cells with a 
different mechanism of generation have been identified in murine studies: (i) the innate 
memory (IM) cells that originate in the thymus [107], (ii) the memory-phenotype cells 
generated on the periphery due to experimental lymphopenia-induced proliferation (LIM) [108, 
109], and (iii) the virtual memory (VM) cells that are converted to the memory phenotype on 
the periphery [110]. The AIMT cells have been found in young adult unchallenged murine 
strains, where they form 10-20% of all CD8+ T-cells. 
Up to now, the only well-established marker for differentiating between the murine antigen 
inexperienced and ‘true’ antigen-experienced central memory CD8+ T-cells is the reduced 
expression of the α4-integrin chain (CD49d) in the AIMT cells, which is common for all three 
subtypes of these cells [111, 112]. Additionally, it has been described in unchallenged murine 
C57Bl/6J strain that the percentage of AIMT cells increases during aging [113, 114].  
Two key cytokines, IL-4 and IL-15, were reported to play a pivotal role in the conversion of 
naive T-cells into the AIMTs. However, until recently, it was unclear which one of these 
cytokines was the main player during the conversion. The question was recently elucidated by 
the group of Tripathi et al., who demonstrated that the cytokine dependency of the AIMTs in 
mice is strain specific. In the Balb/c mouse strain, the AIMT cells are largely dependent on the 
presence of IL-4 supplied by a subset of invariant NK T-cells (iNKT) in the thymus [115] – 
leading to the development of thymic-derived IM cells. Thus, the IL-15-deficiency has only 
partial impact on the AIM T-cell compartment in the Balb/c strain. Meanwhile, the C57Bl/6J 
strain has a very limited number of iNKT cells in the thymus and their AIMT cells are formed 
on the periphery due to the effects of IL-15 [116-118].  
Unfortunately, the functional properties of VM T-cells have not been clearly defined yet. 
Recently, a seminal work by Lee et al. suggested the enhanced protective role of VM T-cells 
compared to naïve T-cells during infection with Listeria monocytogenes [119]. On the other 
hand, far less known is about the possible role of IM cells [120]. Besides the cytokine 
requirements and the site of origin, the differences between VM and IM T-cells are largely 
unknown.  
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6.8.2 Human antigen-inexperienced memory T-cells  
Recently, it has been described that upon adoptive transfer into lymphopenic humanized mouse 
strains, the naïve CD8+ T-cells from humans are able to expand and acquire the memory 
phenotype [121], suggesting that the AIMT cells can develop in humans as well. 
In line of this evidence, a population of a human CD8+ T-cells with some similar characteristics 
to the murine VM CD8+ T-cells has been described in human cord blood as well as in adult 
human blood [113, 122]. The authors have named this population innate-like CD8+ T-cells 
[122] or NK-like CD8+ T-cells [123], since this population expresses characteristic NK-
receptors NKG2A (Killer Cell Lectin Like Receptor C1) and/or killer-cell immunoglobulin-
like receptors (KIR). Furthermore, NK-like CD8+ T-cells express high levels of transcription 
factors Eomes and T-bet that are linked to the CD8+ T-cell differentiation, as well as the IL-2 
receptor subunit β (CD122). Moreover, NK-like CD8+ T-cells were shown to be able to rapidly 
produce high levels of IFNγ after the stimulation with either IL-12/IL-18 or PMA/ionomycin 
(PMA, phorbol 12-myristate 13-acetate) [113, 122]. Based on these features, White et al. 
proposed that these cells might be the human equivalent to the murine VM T-cells [113]. 
Similarly to the murine VM T-cells, the putative human VM T-cells accumulate during aging 
[113, 124] and it has been suggested that VM T-cells acquire the markers of the senescence 
with age as they lose their proliferative capacity in response to the TCR signals [125]. However, 
unlike the murine VM T-cells, these putative human VM T-cells express low levels of CD5. 
More importantly, these cells are negative for the CD27 and CCR7 (C-C Motif Chemokine 
Receptor 7) markers and positive for the CD57 and CD45RA surface markers [113, 122], 
suggesting that these cells are terminally differentiated cells rather than the central memory-
phenotype T-cells [126, 127]. It is however possible that discrepancies in the expression of 
these particular surface markers can be caused by the inter-species differences. 
 
6.8.3 Antigen-inexperienced memory T-cells in leukemia 
Moreover, one of the recently published studies on putative human VM T-cells focuses on the 
possible defect in the VM T-cell compartment during chronic myeloid leukemia (CML), a 
myeloproliferative neoplasm affecting HSC.  
In this study, the patients that have reached complete remission after the treatment with tyrosine 
kinase inhibitor imatinib, were able to restore the numbers of VM T-cells in the peripheral 
blood to the normal levels [128]. Thus VM T-cells could conceivably contribute to the 
development and progression of MDS.  
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7 Aims of the study  
Firstly, the MDS project was focused on better understanding of the progression of MDS, 
specifically how treatment with the hypomethylating drug 5-AC affects the BM 
microenvironment. Therefore, it was necessary to collect a vast number of BM biopsies from 
MDS patients over the course of the disease progression and to analyze the BM plasma from 
the patients treated with 5-AC before and during therapy. In parallel, we have tested the effect 
of the 5-AC treatment in vitro using multiple cell lines of different origin.  
Among others, the occurrence of DNA damage, senescence and the changed cytokine profile 
in the BM microenvironment of MDS patients have been linked to the onset and progression 
of the disease. Currently, the first-choice therapy for the treatment of high-risk MDS is 5-AC 
– a hypomethylating agent with an impact on the epigenetic regulation. Therefore, we have 
investigated the effects of 5-AC on other changes, such as the induction of cell senescence, the 
changes of cytokine levels and the immunomodulation effect.  
Second, we investigated the impact of the common single nucleotide polymorphism C609T of 
the NAD(P)H dehydrogenase (quinone 1) (NQO1) on incidence and survival of MDS patients 
that have reduced levels of the functional NQO1 protein due to this NQO1C609T (NQO1*2) 
polymorphism. The reduction of NQO1 protein levels affects their ability to detoxify benzene 
compounds and to react to oxidative stress. This analysis was done by genotyping the archived 
BM aspirate smears or peripheral blood samples from MDS patients at the Hematology 
department of the General University Hospital in Prague and by analyzing how the NQO1*2 
polymorphism affects the parameters of the progression of the disease.  
Additionally, we inspected the possible augmentation of lenalidomide therapy in relapsed and 
refractory patients with del(5q) MDS by addition of erythropoietin and anti-inflammatory 
glucocorticoid prednisone.  
The third project was focused on deciphering of the driving forces beyond the cell fate choice 
in AIMT CD8+ T-cells. The cell fate choices are driven by the extracellular stimuli such as 
cytokines as well as by the specificity of a TCR expressed in a particular T-cell clone. We have 
hypothesized that VM T-cells might originate from a relatively highly self-reactive CD8+ 
T-cells clones. The aim of this project was to uncover the origin of VM T-cells and to 
characterize the function and differentiation program triggered in this T-cell subset. Moreover, 
in order to better understand the AIMT cell compartment, we have reviewed the current 
literature on the topic and summarized the published works into a review article.  
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7.1 Specific aims  
1. Characterization of the effect of 5-AC therapy on the expression profile of cytokines 
in the BM microenvironment, the answer to DNA damage in the BM of MDS patients 
by using the in vitro models. 
2. Utilization of the candidate markers for the improvement of diagnosis and prognosis 
of MDS patients.  
3. Analysis of the gene expression of naive, VM and antigen-experienced T-cells using 
deep mRNA sequencing to clarify whether VM T-cells use a unique differentiation 
program.  
4. Phenotypic and functional characterization of the monoclonal T-cell populations 
expressing TCRs cloned from the naive or VM T-cell subpopulations. 
5. Comparison of the TCR repertoires expressed by naive and VM T-cell subpopulations 
by sequencing of the TCR-encoding genes to clarify whether TCR specificity drives 
the differentiation of T-cells into VM cells. 
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8 Materials and methods 
The experiments performed for the research described in my dissertation thesis span a wide 
range of methodologies. For the majority of the experiments, either human or murine cells were 
used.  
For in vitro experiments primary BM-MNC and human cell lines were used. For this purpose, 
we have obtained fresh BM samples aspirated from the posterior iliac crest of healthy 
volunteers. The BM plasma was separated by centrifugation and the cytokine milieu was 
analyzed to establish the baseline levels of proinflammatory cytokines. Subsequently, 
erythrocytes were lysed and the BM-MNC were cultivated in vitro and treated with 5-AC. 
Additionally, a selection of human cancer cell lines or immortalized normal cells was utilized 
for the experiments studying the effects of 5-AC administration in vitro. 
In vivo experiments were performed using various transgenic mouse models, mainly derived 
from C57Bl/6 strain. One of those models was C57BL/6-Tg(Ins2-OVA)59Wehi/WehiJ mouse 
(commonly referred to as RIP.OVAhi, here as RIP.OVA) [129]. This mouse strain carries a 
transgene comprising of the full-length chicken ovalbumin cDNA under the control of rat 
insulin promoter, resulting in the soluble form of ovalbumin (OVA) that is highly expressed in 
pancreatic β-cells. We used this model for studying the autoimmune potential of OVA-specific 
VM T-cells. Firstly, we adoptively transferred sorted OVA-specific CD8+ T-cells into 
RIP.OVA mice by intravenous injection into the tail vein. This was followed by intravenous 
injection of either Listeria monocytogenes expressing OVA epitope or DC loaded with OVA 
peptide (SIINFEKL). We utilized a selection of OVA peptide derivatives with variable strength 
of binding to OVA-specific TCR. In case of sufficient strength of binding of OVA 
epitope/peptide to OVA-specific TCR, the stimulated adoptively transferred CD8+ T-cells 
expanded and induced apoptosis in OVA-expressing pancreatic β-cells, subsequently leading 
to the development of experimentally induced autoimmune diabetes due to the lack of insulin. 
We monitored the development of diabetes by measuring blood glucose levels and the presence 
of glucose in urine. 
The experimental data were collected via a wide range of individual protocols. The five key 
approaches for the data collection included: (1) multicolor flow cytometry and fluorescence-
activated cell sorting, (2) a multiplex bead-based assay for evaluation of cytokines, (3) 
immunofluorescence and immunoblotting, (4) quantitative real time-PCR and (5) RNA 
sequencing.  
The additional methodologies are further described in detail in their respective publications.  
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9 Results and discussion  
In recent years, a great effort has been deployed towards better understanding the molecular 
changes in the cells and in the environment that contribute to the development and progression 
of the MDS. In order to gain a better comprehension of the contribution of BM 
microenvironment on the progression of MDS, we investigated the changes in proinflammatory 
cytokine milieu in the MDS BM plasma. We then concentrated our efforts toward finding 
possible prognostic markers for disease progression by analyzing the impact of NQO1*2 
polymorphism on the development and progression of MDS. Additionally, we investigated 
whether the augmentation of lenalidomide treatment by addition of erythropoietin or 
prednisone can increase the response rate in refractory and relapsed del(5q) MDS patients. 
Second arm of my research focused on the characterization of VM CD8+ T-cells. The depletion 
of this population was recently identified in the CML. Thus VM T-cells could as well 
contribute to the MDS pathology. By analyzing this cell population in several mouse models, 
we were able to identify the developmental cues for the formation of VM T-cells, analyze their 
expression profiles and characterize this population with regards to self-tolerance. Finally, we 
compared multiple aspects of the biology between different subsets of AIMT cells and 
concluded that VM T-cells and LIM T-cells likely represent a single subset of AIMT cells. 
Further details are discussed below.  
 
9.1 Changes of the BM cytokine milieu in MDS 
To provide the insights into alterations of the proinflammatory cytokines during MDS 
progression, we measured the proinflammatory cytokine changes in MDS patients from the 
entire spectrum of the IPSS-R score (low-risk, high-risk and AML). We were able to find 
several elevated proinflammatory cytokines in the BM of MDS patients. Specifically, we found 
elevated levels of IL-8, IP-10/CXCL10 (Interferon γ inducible protein 10/C-X-C Motif 
Chemokine Ligand 10), MCP-1/CCL2 (Monocyte Chemoattractant Protein-1/ C-C Motif 
Chemokine Ligand 2) and IL-27 and reduction in the levels of IL-12p70 in the BM of MDS 
patients compared to healthy donors (Publication #1).  
The elevated levels of IL-8 were described in multiple works studying the inflammatory 
diseases and cancers. Under normal conditions, IL-8 promotes trafficking of neutrophils to the 
site of injury and stimulates the formation of neutrophil extracellular traps. In pathogenesis, 
tumor-derived IL-8 promotes an influx of MDSCs into tumor microenvironment, leading 
effectively to diminishing of the anti-tumor immune responses [130]. Recently, CD34+ blasts 
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were identified as the main source of IL-8 in AML. Subsequently, the inhibition of IL-8 
receptor CXCR2 (C-X-C Motif Chemokine Receptor 2) leads to the alleviation of the disease 
via inhibiting the proliferation of aberrant HSC cells [131], making IL-8 axis inhibition an ideal 
candidate for therapeutic intervention in MDS. Additionally, IL-8, IP-10 and MCP-1 contribute 
to the senescence-associated secretome [132, 133].  
IL-12 is produced primarily by the functional APCs after activation via Toll-like receptor 
signaling and is needed for the maturation of DCs. Healthy MSC have the ability to suppress 
the proliferation of nearby T-cells via suppressing the maturation of DCs. In vitro co-culture 
of MDS-MSC with mature monocyte-derived DCs yielded lower secretion of IL-12 than in 
healthy MSC, suggestive of the compromised functions of DCs [134]. Measured decrease in 
the production of IL-12 in all MDS groups in our cohort thus indicates an impaired capacity to 
induce effective adaptive immune responses in MDS patients.  
Another member of the IL-12 family, IL-27, is produced by APCs and is involved in the 
immune homeostasis via inhibition of Th17 differentiation [135]. Additionally, IL-27 
modulates Treg responses by inhibiting the production of IL-2 [136, 137]. Both of these cell 
types play a major role in the progression of MDS [36]. 
In the effort to better understand the effects of 5-AC on the BM, we assessed the 
proinflammatory cytokine secretion profiles of the several cell lines and the healthy BM 
mononuclear cells (BM-MNC) from fresh BM aspirates after the treatment with 5-AC in vitro. 
Indeed, we showed that 5-AC induces expression of proinflammatory cytokines both in several 
cancer cell lines as well as in immortalized MSC and in BM-MNCs. The levels of IL-8, IL-27 
and MCP-1 were further elevated in BM plasma of high-risk MDS patients during 5-AC 
therapy, with moderately higher levels of IL-8 and IL-27 in the patients not responding to the 
therapy.  
Additionally, the inflammatory co-morbidities such as diabetes mellitus or rheumatoid arthritis 
contributed to the elevated levels of IL-8 and MCP-1 in low-risk MDS patients.  
Notably, the levels of cytokines measured from the peripheral blood plasma at the time of BM 
aspiration did not strictly correlate with the cytokine levels in the BM plasma, indicating that 
the estimation of cytokines from the PB plasma could be insufficient to obtain an accurate 
projection of the cytokine milieu in the BM niche.  
Overall, all forms of MDS feature a deregulated proinflammatory cytokine landscape in the 
BM and such alterations are further augmented by the 5-AC therapy of high-risk MDS patients.  
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9.2 Utilization of candidate markers for the improvement of diagnosis and prognosis 
of MDS patients.  
Although MDS is a serious illness known for several decades, the molecular pathogenesis and 
the question why the disease evolves to AML remain unclear. Genetic, epigenetic, and 
immunopathological factors most likely contribute to the pathogenesis of MDS [138-140].  
About 50% of MDS patients have cytogenetic abnormalities, mostly unbalanced chromosomal 
losses and gains with profound impact on the expected OS of these patients. Recently, a lot of 
effort has been directed towards the identification of somatic mutations in stem cells and other 
progenitors that could influence the initiation and progression of MDS [141, 142]. Somatic 
mutations occur in about 80% of MDS patients [140, 143]. The presence of somatic mutations 
can lead to the dysplastic hematopoiesis caused by the apparent growth advantages of the 
mutation-ridden aberrant HSC clones. These somatic mutations could be a consequence of the 
BM exposure to the toxic chemicals, as in the case of secondary MDS. 
Inborn changes that lead to the subsequent MDS evolution were so far only described in rare 
inherited BM failure syndromes such as Fanconi anemia, Diamond-Blackfan anemia, 
congenital dyskeratosis, and Shwachman-Diamond syndrome [144].  
In our effort to find a prognostic marker for the development and progression of MDS, we 
decided to focus on the NQO1, an enzyme involved in detoxification of quinones, reduction of 
oxidative stress, and stabilization of p53 (Publication #2). 
Under normal conditions NQO1 protein is not detected in human BM cell aspirates or in the 
purified CD34+ blast cells, however upon benzene exposure, both of these cell types are 
inducible for the NQO1 activity [145]. The NQO1 gene contains the Nrf2-binding site in its 
promoter region and its expression is regulated by the Keap1/Nrf2/ARE pathway that is 
essential for the adaptation to oxidative stress (Keap1, Kelch Like ECH Associated Protein 1; 
Nrf2, Nuclear Factor, Erythroid 2 Like 2; ARE, antioxidant response element). The NQO1 
protein is predominantly present in the BM stroma, endothelial cells and in BM adipocytes 
[146] and plays a role in endothelial adhesion of hematopoietic cells [147]. 
The naturally occurring germline polymorphism of NQO1C609T (NQO1*2) results in loss of the 
NQO1 activity and rapid degradation of the NQO1*2 protein due to the formation of an 
unstable tertiary structure [148]. The individuals homozygous for this polymorphism have no 
NQO1 activity, while the heterozygotes have low to intermediate activity that can be 
insufficient during high genotoxic stress, e.g. anthracycline chemotherapy and exposure to 
toxic radicals caused by iron overload [149]. Recently, several studies indicated that 
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individuals with NQO1 deficiency may be at increased risk for the development of MDS and 
leukemia [150-152].  
In our study, we focused on the possible influence of NQO1 enzyme activity on the course of 
the disease itself, the impact of NQO1*2 polymorphism on the severity of the disease, and the 
overall survival. Considering the clinical heterogeneity of the MDS, we have analyzed the 
correlation of NQO1*2 polymorphism with the various IPSS-R score groups and known 
prognostic factors.  
Firstly, we have found a higher presence of NQO1*2 among MDS/AML patients in 
comparison to a large population cohort of previously published healthy controls. Therefore, 
in agreement with previous studies our data indicate that there is a predisposition to the MDS 
development among NQO1*2 bearers.  
Moreover, our results revealed the higher presence of NQO1*2 in the MDS subgroups with 
higher BM blasts percentage and with karyotype abnormalities. However, we did not find any 
correlation with the specific cytogenetic aberrations, as was described by Zachaki et al. [153], 
probably due to the relatively smaller sample size of patients with cytogenetic aberrations.  
Further, we examined the impact of NQO1*2 polymorphism on the OS in MDS patients with 
normal karyotype and found a striking difference in the OS among low-risk patients. In our 
cohort, the patients with fully functional NQO1 survived from the date of diagnosis on average 
nearly twice as long as the patients with NQO1*2. Moreover, the NQO1*2 polymorphism 
impacted the OS among 5-AC-treated MDS patients. The patients with NQO1*2 progressed 
faster than NQO1 and thus were eligible for the 5-AC treatment sooner after the diagnosis than 
NQO1.  
Recently, Rassool et al. showed in the murine model that an increase in oxidative stress plays 
a role in the development and progression of myeloid leukemia [154]. One of the sources of 
the oxidative stress in MDS is iron overload induced by regular erythrocyte transfusions that 
are affecting over 60% of MDS patients and shortening the expected OS [155].  
Superabundant intracellular ferric ions give rise to the production of highly reactive hydroxyl 
radicals that can induce the oxidative damage of lipids, proteins, and DNA and can trigger cell 
death [156]. Production of toxic radicals and the development of oxidative stress can inflict the 
damage of hematopoietic progenitors, genetic instability, and worsen the BM 
microenvironment, resulting in the emergence of novel mutations and genesis of additional 
clonal aberrations [157].  
NQO1 is one of the enzymes needed for the regulation of oxidative stress caused by the 
accumulation of hydroxyl radicals during the iron overload. The presence of several 
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polymorphisms in the genes coding for the enzymes in the antioxidant defense system (Nrf2, 
NQO1, NOS3, and HO-1) concurrent with the iron overload can have impact on the etiology 
of breast cancer [158]. Since the expression of Nrf2 and NQO1 can be upregulated by the 
dietary iron overload [159], we wanted to ascertain whether the decreased NQO1*2 
cytoprotective function can play a role in the progression of MDS in patients burdened with 
increased ferritin levels and iron overload. Indeed, we have found significantly shortened OS 
among patients affected by both the presence of NQO1*2 polymorphism and increased serum 
ferritin levels when compared to other patient subgroups.  
In conclusion, the presence of NQO1*2 alleles is associated with a higher probability of MDS 
development, faster disease progression, sensitivity to blood transfusion-provoked iron 
overload, and shorter expected OS indicating that the knowledge about NQO1 polymorphism 
among MDS patients at the time of the diagnosis, as well as the early administration of iron-
chelating agents to patients affected both by the dysfunctional NQO1 allele and iron overload, 
might be beneficial for the control of disease progression.  
Another approach on how to improve the response rate in low-risk MDS with del(5q) 
chromosomal aberration focused on the combination of lenalidomide therapy with 
erythropoietin and/or glucocorticoid prednisone (Publication #3). The use of lenalidomide is 
approved for low-risk MDS patients with del(5q) chromosomal aberrations. This group of 
MDS patients is very specific because of their long OS, progressive macrocytic anemia with 
increased platelet count and a high rate of transfusion dependency.  
By binding to CRBN, lenalidomide modifies the substrate specificity of E3 ubiquitin ligase 
CRL4 and influences the proteasomal degradation of its target proteins. One of these proteins 
is casein kinase 1A1 (CSNK1A1) that is haploinsufficient in del(5q) cells. The relative lack of 
CSNK1A1 results in the increased levels of β-catenin that support the proliferation of aberrant 
HSC with del(5q) [160]. However, when the levels of CSNK1A1 drop beyond a certain level, 
this induces the p53-dependent apoptosis. The treatment with lenalidomide thus selectively 
induces apoptosis in the del(5q) HSCs [161].  
An additional effect of lenalidomide is the stimulation of erythropoiesis, leading to the common 
loss of transfusion dependency [162]. Despite its efficacy and the initial response in 60-70% 
of the patients, approximately 30% of the initially responding patients eventually relapse [163].  
Recently, the group of Basiorka et al. explained the possible mechanism for the restorative 
ability of lenalidomide on erythropoiesis. Lenalidomide treatment of normal BM-MNC in vitro 
increased the erythropoietin sensitivity by inhibiting the E3 ubiquitin ligase RNF41 that 
regulates the erythropoietin receptor turnover (RNF41, Ring Finger Protein 41) [164]. 
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Simultaneously, Toma et al. successfully utilized the combination of erythropoietin and 
lenalidomide in transfusion-dependent refractory low-risk MDS without del(5q) [165]. 
Moreover, in vitro study by Narla et al. demonstrated that the treatment with lenalidomide with 
corticosteroid drug dexamethasone has an additive effect on the expansion of erythroid 
progenitors [166].  
Consequently, we postulated that the combination of corticosteroid prednisone, erythropoietin 
and lenalidomide should lead to the reduction of transfusion dependency in refractory MDS 
and in relapsed patients with del(5q) MDS. The success of this clinical management was 
confirmed in our study cohort. Five out of seven relapsed del(5q) MDS patients treated with 
lenalidomide in our cohort achieved transfusion independence in response to the addition of 
either erythropoietin alone or in combination with prednisone. As per non del(5q) MDS group, 
only one out of ten treated MDS patients achieved transfusion independence after combination 
therapy with lenalidomide and erythropoietin.  
Hence, the treatment with lenalidomide represents an effective solution for del(5q) MDS group 
and the combination with prednisone and erythropoietin may be beneficial for initial non-
responders or patients after therapy failure. 
 
9.3 The role of homeostatic TCR signals in the formation of VM CD8+ T-cells  
As discussed previously, T-cells represent a hematopoietic lineage that is involved in most 
adaptive immune responses and play a role in hematopoiesis. T-cells make multiple cell-fate 
decisions during their maturation and life cycle. The cell-fate choices are driven by the 
extracellular stimuli (e.g. cytokines) as well as by the specificity of a TCR expressed in 
individual T-cell clones. 
In this project (Publication #4), we focused on the effect of homeostatic TCR signals on the 
development of VM T-cells. Although constituting 10-20% of all peripheral CD8+ T-cells in 
mice, the origin, biological roles, and relationship of VM T-cells to naïve and foreign antigen-
experienced memory T cells are incompletely understood. 
By analyzing the gene expression profiles of naive, VM and antigen-experienced T-cells via 
deep mRNA sequencing, we were able to uncover that VM T-cells represent a distinct T-cell 
population. Further assessment of the previously established signature genes for memory 
program and for naïve program uncovered that VM T-cells represent an intermediate stage 
between naïve and memory T-cells.  
36 
 
Next, we intended to better understand the forces driving differentiation to the VM T-cell 
program. We tested a hypothesis that the level of self-reactivity of a given T-cell has an impact 
on the formation of VM T-cell. For this, we benefited from the previously published 
observations that the coupling frequency between CD8 co-receptor and Lck kinase (LCK 
Proto-Oncogene, Src Family Tyrosine Kinase) is a limiting factor for TCR signaling in 
thymocytes [167, 168].  
We used a transgenic mouse model expressing a CD8.4 chimeric co-receptor, consisting of the 
extracellular portion of CD8 fused to an intracellular part of CD4 [168]. This fusion leads to a 
supraphysiological coupling of the CD8 co-receptor to Lck, a kinase that initiates a TCR signal 
transduction. The resulting CD8.4 T-cells have enhanced TCR signaling to self-antigens [169], 
which allowed us to address the role of homeostatic TCR signaling in VM T-cell formation. 
We found that strong homeostatic TCR signaling introduced by a higher CD8-Lck coupling in 
CD8.4 T-cells leads to a higher frequency of differentiation into VM T-cells in a polyclonal 
repertoire. Furthermore, by introducing the CD8.4 transgene into mice with monoclonal T-cell 
populations, we ascertained that the high level of self-reactivity predetermines the VM 
differentiation program in CD8+ T-cells. 
Next, we compared the TCR repertoires expressed by naive and VM T-cell subpopulations by 
sequencing the TCR-encoding genes to elucidate whether the TCR-specificity drives the 
differentiation of T-cells into VM developmental program. Indeed, we found that the naïve and 
VM T-cells use distinct TCR repertoires, which we directly confirmed by generating retrogenic 
monoclonal T-cell populations expressing TCRs cloned from the naive or VM T-cell 
subpopulations [170] that recapitulated the same cell fate choice.  
Until recently, it was generally acknowledged that the antigen-experienced memory T-cells 
surpass the naïve T-cells and induce a much faster and stronger response to cognate antigen 
stimulation [171-173]. Tearing down the scientific dogma, it was shown that the response of 
naïve T-cells to antigen stimulation can be under certain conditions stronger than the response 
of memory T-cells [174-176]. In line of this evidence, the comparison between VM T-cells and 
naïve T-cells showed that VM T-cells better respond to inflammatory cytokines IL-12 and IL-
18 [110], more rapidly generate short-lived effectors [177], and better protect against Listeria 
monocytogenes infection [177, 178] than naïve T-cells. However, our results clearly showed 
that the VM T-cells were less efficient than naïve T-cells with the same TCR specificity in 
inducing the experimental autoimmune diabetes. A partial explanation of this phenomenon lies 
in the lower upregulation of CD49d and CD25 in VM T-cells than in naïve T-cells upon the 
activation with sub-optimal antigen. Our findings thus demonstrate that the induction of VM 
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developmental program in the highly self-reactive T-cells can serve as a compensatory 
mechanism in the protection against autoimmunity.  
Subsequently, we summarized the published findings about different subtypes of AIMT cells, 
such as cytokine requirements for their formation, the impact of TCR specificity on the 
differentiation process, gene expression signature markers and strength of the immune 
response. Based on these parameters, we concluded that VM T-cells and LIM T-cells likely 
represent a single subset of AIMT cells. We have proposed to call this subset “homeostatic 
memory T-cells” (Publication #5).  
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10 Conclusion 
In my dissertation thesis, I discussed five projects dealing with the pathophysiological 
development and differentiation of cells during hematopoiesis. Three projects were focused on 
the pathophysiological changes of the hematopoiesis during the development and progression 
of MDS.  
In these projects, we showed that the proinflammatory cytokine milieu in the BM changes 
during the progression of the disease. We found an increase in IL-8, IP-10, MCP-1 and IL-27 
and decrease in IL-12 levels compared to healthy controls. Repeated sampling of high-risk 
MDS patients showed an increase in IL-8, IL-27 and MCP-1 over the course of 5-AC therapy.  
Moreover, we identified NQO1*2 as a novel marker for the prediction of the pace of MDS 
progression and expected OS. Third, we confirmed that the addition of erythropoietin and/or 
prednisone improves the response rate of relapsed and del(5q) MDS patients treated with 
lenalidomide. 
Second arm of my research focused on the characterization of VM CD8+ T-cells. We 
established the VM T-cell development as a novel cell-fate decision checkpoint, determined 
by their TCR self-reactivity. Next, we described the molecular mechanisms driving the 
formation of VM T-cells and discovered that although VM T-cells develop from the highly 
self-reactive cells and acquire a partial memory program, they are less efficient in inducing the 
experimental autoimmune diabetes than naïve T-cells.  
Finally, we compared multiple aspects of the biology between different subsets of AIMT cells 
and concluded that the VM T-cells and LIM T-cells likely represent a single subset of AIMT 
cells. We have proposed to call this subset “homeostatic memory T-cells”.  
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10.1 Summary of major findings  
 
1. The proinflammatory cytokine milieu in the BM changes during the progression of the 
MDS. The patients undergoing the 5-AC therapy experienced an increase in the levels 
of proinflammatory cytokines IL-8, IL-27 and MCP-1 over the course of therapy.  
2. NQO1*2 is a novel candidate marker for the prediction of the pace of MDS progression.  
3. Addition of erythropoietin and prednisone improves the response rate of relapsed and 
del(5q) MDS patients treated with lenalidomide. 
4. Naïve, antigen-experienced and VM T-cells represent distinct cell populations with 
unique expression profiles. The expression profile of VM T-cells corresponds to the 
intermediate stage between naïve and antigen-experienced memory T-cells.  
5. VM T-cell development is a novel cell-fate decision checkpoint, determined by their 
TCR self-reactivity. TCR specificity drives differentiation of T-cells into VM cells. 
6. VM T-cells acquire partial memory program, but they are less efficient in inducing the 
experimental autoimmune diabetes than naïve T-cells.   
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11 Publications  
The fulltexts of the publications included in this thesis can be found in the last section of the 
thesis. 
11.1 List of the publications included in the thesis 
 
#1 Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes 
patients treated with 5-azacytidine. Moudra A, Hubackova S, Machalova V, 
Vancurova M, Bartek J, Reinis M, Hodny Z, Jonasova A. Oncoimmunology. 2016 May 
13;5(10):e1183860. PMID: 27853634  
 
#2  NQO1*2 polymorphism predicts overall survival in MDS patients. Moudra A, Minarik 
L, Vancurova M, Bartek J, Hodny Z, Jonasova A. British Journal of Haematology. 2019 
Jan;184(2):305-308. PMID: 29363755  
 
#3 Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a 
Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to 
lenalidomide in refractory or relapsed patients). Jonasova A, Neuwirtova R, Polackova 
H, Siskova M, Stopka T, Cmunt E, Belickova M, Moudra A, Minarik L, Fuchs O, 
Michalova K, Zemanova Z. Leukemia Research. 2018 Jun;69:12-17. PMID: 29614393  
 
#4 Strong homeostatic TCR signals induce formation of self-tolerant virtual memory CD8 
T cells. Drobek A*, Moudra A*, Mueller D, Huranova M, Horkova V, Pribikova M, 
Ivanek R, Oberle S, Zehn D, McCoy KD, Draber P, Stepanek O. EMBO Journal. 2018 
Jul 13;37(14). PMID: 29752423 * Equal contribution  
 
#5 Opinion: Virtual memory CD8 T cells and lymphopenia-induced memory CD8 T cells 
represent a single subset: Homeostatic memory T cells. Pribikova M, Moudra A, 
Stepanek O. Immunology Letters. 2018; 203:57-61. PMID: 30243945  
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11.2 Contribution  
 
Ad #1  Dynamic alterations of bone marrow cytokine landscape of myelodysplastic 
syndromes patients treated with 5-azacytidine.  
I performed all experiments, sample collection and analysis of the data (Figure 1-4) and wrote 
the manuscript under the supervision of Dr. Zdeněk Hodný, Dr. Anna Jonášová and Dr. Jiří 
Bartek. 
 
Ad #2 NQO1*2 polymorphism predicts overall survival in MDS patients. 
I performed the genotyping, sample collection, created the database of the patient data, 
designed the study and performed the statistical analysis (Figure 1-2) as well as wrote the 
manuscript under the supervision of Dr. Zdeněk Hodný, Dr. Anna Jonášová and Dr. Jiří Bartek. 
 
Ad #3  Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience 
of a Czech hematology center. (Positive effect of erythropoietin ± prednisone 
addition to lenalidomide in refractory or relapsed patients). 
I contributed to the project by performing the statistical analysis of the patient data (Figure 1) 
and wrote the manuscript under the supervision of Dr. Anna Jonášová.  
 
Ad #4  Strong homeostatic TCR signals induce formation of self-tolerant virtual memory 
CD8 T cells. 
I performed the research, data collection (Figure 3 - 6), and data analysis of the experiments 
and wrote the manuscript under the supervision of Dr. Ondřej Štěpánek. 
 
Ad #5 Opinion: Virtual memory CD8 T cells and lymphopenia-induced memory CD8 T 
cells represent a single subset: Homeostatic memory T cells. 
I contributed to the review by writing parts of the manuscript and the reviewing the source data 
for the publication under the supervision of Dr. Ondřej Štěpánek.  
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